Opinion

Video

Comparing Afami-Cel Outcomes With Chemotherapy and Other Treatment Options

A panelist discusses how afamitresgene autoleucel (afami-cel) has shown encouraging response rates and durability of response in a heavily pretreated population where standard chemotherapy typically yields limited benefit, though direct comparisons are challenging because of the lack of randomized trials and the distinct patient populations treated with different therapeutic approaches.

Video content above is prompted by the following:

  • How does afami-cel’s outcomes compare with chemotherapy, other immunotherapies, and investigational agents?

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All
18th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies
Video

18th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies

Apr 8th 2025 - May 14th 2025

online-activity
View More
Updates and Innovations in Nonopioid Pain Management Strategies for Breast Cancer Patients Postsurgical Intervention
Video

Updates and Innovations in Nonopioid Pain Management Strategies for Breast Cancer Patients Postsurgical Intervention

Apr 7th 2025 - Apr 8th 2026

online-activity
View More
Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | Arkansas
Video

Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | Arkansas

Apr 3rd 2025 - May 9th 2025

online-activity
View More
Related Content
Global Oncology | Image Credit: © Katsyarina – stock.adobe.com
April 18th 2025

Global Analysis Shows Significant Variability in Sarcoma Clinical Trial Availability

Gina Z. D’Amato, MD
February 9th 2023

D'Amato Discusses Research and Resistance Mechanisms in Sarcoma and Gastrointestinal Stromal Tumor

Malignant Perivascular Epithelioid Cell Tumors | Image Credit: © Cornflakesei - stock.adobe.com
April 9th 2025

Intravenous Sirolimus Shows Tolerability, Early Efficacy in Malignant PEComa

Somaiah Shares Insight on the Changing Landscapes of GIST, TGCT, and RAS/RAF-Mutant Tumors
December 29th 2022

Somaiah Shares Insight on the Changing Landscapes of GIST, TGCT, and RAS/RAF-Mutant Tumors

Nirogacestat in Desmoid Tumors | Image Credit: © Katsyarina – stock.adobe.com
March 27th 2025

Nirogacestat Provides Long-Term Benefits in Desmoid Tumors

Image Credit: Maris – stock.adobe.com
March 27th 2025

Elective Discontinuation May Be Possible With Larotrectinib in TRK Fusion–Positive Sarcomas